A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome

A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome

Abstract Background Gamma-aminobutyric acid (GABA) system deficits are integral to the pathophysiologic development of fragile X syndrome (FXS). Ganaxolone, a GABAA receptor positive allosteric modulator, is hypothesized to improve symptoms such as anxiety, hyperactivity, and attention deficits in c...

Full description

Bibliographic Details
Main Authors: Andrew Ligsay, Anke Van Dijck, Danh V. Nguyen, Reymundo Lozano, Yanjun Chen, Erika S. Bickel, David Hessl, Andrea Schneider, Kathleen Angkustsiri, Flora Tassone, Berten Ceulemans, R. Frank Kooy, Randi J. Hagerman
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Journal of Neurodevelopmental Disorders
Subjects:
Fragile X syndrome
Ganaxolone
Clinical trial
Children
Adolescents
Online Access:http://link.springer.com/article/10.1186/s11689-017-9207-8

Internet

http://link.springer.com/article/10.1186/s11689-017-9207-8

Similar Items